Taking the lead: Corvus Pharmaceuticals Inc (CRVS)

With 1.11 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.92 million shares. The 52-week range on CRVS shows that it touched its highest point at $10.00 and its lowest point at $1.30 during that stretch. It currently has a 1-year price target of $14.80. Beta for the stock currently stands at 0.90.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRVS was down-trending over the past week, with a drop of -17.40%, but this was down by -25.38% over a month. Three-month performance dropped to -52.18% while six-month performance fell -5.06%. The stock gained 70.56% in the past year, while it has lost -26.36% so far this year. A look at the trailing 12-month EPS for CRVS yields -0.93 with Next year EPS estimates of -0.47. For the next quarter, that number is -0.12. This implies an EPS growth rate of -64.58% for this year and 49.55% for next year. EPS is expected to decline by -2.42% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 19.89%.

Float and Shares Shorts:

At present, 62.58 million CRVS shares are outstanding with a float of 47.01 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRVS since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.90163 being high and -$0.95172 being low. For CRVS, this leads to a yearly average estimate of -$0.92167. Based on analyst estimates, the high estimate for the next quarter is -$0.1 and the low estimate is -$0.13. The average estimate for the next quarter is thus -$0.12.